# Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma

> **NCT00996957** · PHASE1 · COMPLETED · sponsor: **Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA** · enrollment: 37 (actual)

## Conditions studied

- Advanced Solid Tumors
- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** ACE-041

## Key facts

- **NCT ID:** NCT00996957
- **Lead sponsor:** Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2012-06
- **Final completion:** 2012-10
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2013-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00996957

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00996957, "Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00996957. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*